Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of ...
GM1 gangliosidosis, caused by biallelic variants in GLB1, results from deficiency of lysosomal β-galactosidase, which degrades GM1 ganglioside. This fatal neurodegenerative disease currently has no ...
First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival. In a milestone for the hematologic ...
NEO-811 is a novel molecular glue degrader intended to fully block a key clear cell renal cell carcinoma signaling pathway via cereblon-dependent target degradation. The primary outcome measures for ...
The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ...
Systemic Olvi-Vec administration in lung cancer trials shows feasibility, tolerability, and promising clinical responses in heavily pretreated patients. OLVI-VEC-SCLC-202 trial in SCLC shows a 33% ...
(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will ...
For the quickest way to join, simply enter your email below and get access. We will send a confirmation and sign you up to our newsletter to keep you updated on all your gaming news.
Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on its candidate for metastatic or refractory cancers, INT230-6. The asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results